AAO | videos

Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.

Ram Liebenthal, U.S. general manager for Heidelberg Engineering, discusses how the company continues to invest in the Spectralis platform in terms of hardware and software improvements.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Josh Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.

Ted Leng, MD, MS, Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Steven D. Schwartz, MD, Stein Eye Institute, UCLA, highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data."

Anne L. Coleman, MD, president of the American Academy of Ophthalmology, offers a preview of its virtual 2020 annual meeting.

Prof. Marie-José Tassignon, past chief and chair, Department of Ophthalmology, Antwerp University and University Hospital Antwerp, Belgium, expands on her upcoming AAO presentation by providing an overview of her novel technique in performing a risk-free posterior capsulorhexis.

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.